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ABSTRACT
Obesity is a disorder that consists of many factors, which has become a global epidemic since it is associated with various
crucial diseases, such as diabetes, cardiovascular diseases, hypertension, stroke, sleep apnea, as well as other conditions.
In order to manage obesity, a variety of strategies are taken into account in order to direct attention on those with current
weight problems as well as those that are at a high risk of developing obesity. Therefore, obesity prevention should be
focused during the early ages as there is a high risk of developing it in the later years. This article focuses on the risk
factors of obesity as well as many preventive treatment options for obesity.
Keywords: Obesity, Sleep Apnea.

INTRODUCTION
Obesity is defined as the body mass index equal to
or greater than 30 and less than 40, severe obesity is
when the BMI is greater than or equal to 40, and
being overweight is when the BMI is equal to or
greater than 25 and less than 30.[1,2] Obesity has been
declared an epidemic and is a major global problem
among both men and women. In the U.S. one third
of the adults are obese, which is the leading cause of
preventable death.[3-5] Worldwide prevalence of
obesity and overweight increased from 29% in 1980
to 37% in 2013 among adult men and women.[4] If
the linear trend continues, then 51% of US adults
will be obese by 2030 with 130% increase in severe
obesity.[1] Obesity is associated with increased risk
of diabetes mellitus, cardiovascular diseases,
hypertension, hyperlipidemia, stroke, arthritis,
obstructive sleep apnea, and many other diseases.[3,4]
The prevalence of childhood and young adult obesity
is significantly increasing due to unhealthy life style
habits, and decrease in physical activity that is
influenced by parental sedentary life style.[2,5] The
estimated cost of obesity in the USA is more than
$147 billion annually.[1,3]
Complications of Obsesity
Firstly, Type 2 diabetes is a severe risk for obese
individuals. In a study by Daosi et al., of 3,637
patients, 86% of the obese patients had type 2
diabetes.[6] Type 2 diabetes and obesity are directly
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correlated because insulin resistance leads to raised
blood glucose levels which in turn increases the
adipose tissue fat.[7] Body fat is divided into 80%
subcutaneous fat and 20% visceral fat of the total.[7]
However, visceral fat is a greater contributor to
obesity since visceral fat cells are correlated to the
excessive production of adipocytokines which
causes inflammation and insulin resistance.[7] The
adipocytes in the visceral tissue have a higher rate of
lipolysis, which is the breakdown of fats into fatty
acids compared to the subcutaneous fats. Obesity
leads to the release of excessive fatty acids from an
increase in lipolysis. The increase in fatty acid
(lipotoxicity) causes insulin receptor dysfunction
leading to insulin resistance.[7] In normal individual,
blood sugar levels don't rise, as insulin will turn
down gluconeogenesis, while individuals with
insulin resistance, the blood sugar levels continue to
increase because gluconeogenesis continues.[7] The
rapid increase in the number of people with type 2
diabetes is directly correlated to weight gain and
obesity.
Along with type 2 diabetes, cardiovascular disease is
another risk for obese individuals. Cardiovascular
disease (CVD) is a heart condition that involves
diseased vessels, structural problems, and blood clots
and is the leading cause of death worldwide except
in Africa.[8] According to Bacha, longitudinal studies
in adults show that obesity is a risk factor for
coronary heart disease and heart failure; an
increment of 1 unit of body mass index increases the
risk by 5% for men and 7% for women.[9] Adipose
tissue is surrounded by an extensive capillary
network, and after a meal, the adipose tissue blood
flow increases. Adipose tissue is what makes up a
majority of the total body weight, and a big amount
of fluid can be seen in the interstitial space of the
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Treatment Options
Obesity is a severe, enduring medical condition,
which leads to various conditions that are life
threatening. In fact, it is continuing to increase
rapidly worldly which is quite debilitating.
Therefore, in order to control the obesity rates, there
are many rational strategies that overcome the
foremost issues associated to the prevention of:
I.)
Normal weight individuals that are
developing into over weight
II.)
Overweight individuals who are
becoming obese
III.)
Individuals that used to be overweight
or obese and are regaining weight and
IV.)
An established condition that is
becoming worse.[1]
Helpful management strategies must be integrated in
order to help solve the issues. The evaluation of
obesity must be completed frequently by the

measuring the BMI, measuring the waist
circumference, etc. in order to gauge risk factors.
Based off of the evaluation, the designated treatment
will be recommended. Treatments involve lifestyle
modification, such as diet modification and
increased physical activity, behavioral therapy,
pharmacology therapy, and bariatric surgery.
Lifestyle Modification
Diets, such as high protein and low carbohydrate
diets, very low fat diets, very low calorie diets, on
line weight loss diets, Mediterranean diets, balanced
nutrient diets, and portion controlled diets are
effective and induce weight loss.[13]
In two major studies the DPP and Look AHEAD,
body weight reduction on an average of 5-10 kg
occurs mainly in first 6 months. Also significant
improvement in lipid levels and blood pressure were
observed.[13]
The Framingham Nutrition study focused on diet
quality, which revealed that a lower quality diet
(higher nutritional risk scores) were at a greater
likelihood to become overweight or obese.[3]
Decreasing the daily caloric intake by 500
kilocalories leads to a decrease in body weight
between 5-10 % and a decrease in body mass index
(BMI) by 2.0 and 2.9 kg/ m2.[14] All diet plans help
weight loss and no one diet is superior, but the
important thing is to adhere to the diet, and the
negative energy balance through restriction of
calories, which helps achieve weight loss.[13,15]
One change in lifestyle is participating in physical
activity to reduce sedentary behavior.[2] Evidence
shows that participating in adequate physical activity
improves various factors, such as energy balance,
maintains weight after weight loss, increases
sensitivity to insulin, enhances beta-cell function,
and regulates both blood pressure and cholesterol.[16]
Rigorous, medium to high intensity workouts have a
more significant impact on weight loss compared to
slow walking. In order to reduce the risk of chronic
disease, exercising about thirty minutes per day is
sufficient, however, to maintain healthy weight or
lose weight, at least an hour per day is necessary.
Due to sedentary life style, non-exercise activity
thermogenesis (NEAT) is significantly declined.
Modification of sedentary life style by climbing
stairs instead of using elevators, walking after a
meal, parking away from the work place, doing work
while standing etc. will prevent overweight and
obesity.[17]
Behavioral Therapy
Lifestyle changes by reducing calorie intake and
increasing physical activity can result in about 10%
loss of initial body weight. To fortify behavioral
therapy for management of obesity is to assist a shift
from maladaptive eating and exercise patterns to
healthy eating and regular exercise. The behavioral
therapy factors are self-monitoring, stimulus control,
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adipose tissue. This large amount of fluid plays a
vital role in obese individuals that have
cardiovascular diseases if the volume is redistributed
into the circulation. Blood flow in the adipose tissue
is adjusted by beta-receptors that cause
vasodilation;[10] therefore, the fluid in the interstitial
compartment is not attainable. Although cardiac
output increases with total mass fat, the insertion in
adipose tissue decreases with increasing obesity.
Generally, for obese individuals, the cardiac
workload is greater, which causes ventricular and
atrial chamber dilation and cardiomyopathy. The
most frequent death in obese individual is due to
dilated cardiomyopathy that causes fatal arrhythmia,
where the heart does not beat properly.[10] As was
seen with type 2 diabetes, there is a strong
correlation between obese patients who suffer from
cardiovascular disease.
Hypertension is the most common health problem
related to obesity.[11] It is roughly two times as
prevalent among the obese population compared to
the
non-obese
population.[11]
White
coat
hypertension, confirmatory ambulatory blood
pressure parameters, and nondipping blood pressure
was higher in overweight and obese people in
comparison to normal weight individuals.[12]
Abnormal renal sodium and water reabsorption,
impaired pressure natriuresis, and activation of the
sympathetic nervous system which plays a major
role in obesity-related hypertension. Obese
individuals have higher day and nighttime heart rate
variability, and impaired decrease in blood pressure
at night compared to normal weight individuals.[12]
Juonala et al found that obese children were more
likely to have hypertension, diabetes type 2,
cardiovascular diseases, elevated low-density
lipoprotein levels, and low high-density lipoprotein
levels. However, obese children who developed into
adult normal weight will have significant lower
cardiovascular risk.[29]
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Pharmacology Therapy
National Institutes of Health suggested that every
individual begins treatment with diet modification,
exercise, and behavioral therapy. Pharmacotherapy
is the next step if these lifestyle changes do not
foster a weight loss equivalent to 10 % of initial
weight or at least 0.5 kg/week over 6 months.
Pharmacotherapy is recommended for individuals
with a body mass index (BMI) greater than 30
kg/m2 or a BMI higher than 27 kg/m2 plus one or
more associated comorbidities like hypertension,
dyslipidemia, coronary artery disease, type 2
diabetes mellitus, or sleep apnea. After initiating
therapy within the first 4 weeks if the patient does
not lose at least 2 kg, then the response to that
medication is low, and the patient should increase
the dosage, stop the previous drug, or substitute it
with another type of medication. The medication
may be continued if significant weight loss occurs
on a medication or the initial weight loss is
maintained since it is effective and the side effects
are endurable.[22]
Currently the available medications are Orlistat,
Liraglutide, Naltrexone/Bupropion, Phentermine/
Topiramate ER, and Lorcaserin—the Food and Drug
Administration approve the later 4 in last 4 years for
chronic weight management. The guidelines setup
by FDA for approval of weight loss medications is at
least a 5% mean weight loss after 1 year of
treatment, in the study at least 35% of the patients
treated achieved this weight loss goal.[23]
Orlistat is an inhibitor of gastric and pancreatic
lipases that result in malabsorption of approximately
30% of ingested fat. It has no side effects but since
there is no absorption, it needs derivative fat-soluble
vitamins to avoid vitamin deficiency. In a
randomized study, 892 subjects received placebo 3
times a day or orlistat, 120 mg 3 times a day for 52

wk. In the first year, subjects that were treated with
orlistat lost more weight - 8.76kg than placebo
treated subjects- 5.81 kg. Orlistat leads to important
reductions in total and low-density lipoprotein
cholesterol and in systolic and diastolic blood
pressure.[22]
Combination of Phentermine a sympathomimetic
drug and Topiramate an antiepileptic drug has
demonstrated efficacy in reducing weight by appetite
suppression, decreased food consumption, increase
satiety, increase metabolism and altering taste. The
EQUIP
trial
evaluated
2
doses
of
phentermine/topiramate ER in patients with obesity.
The average body mass reduction ranged from 5.1%
to 10.9% and the responses were dose related. For
patients taking the maximum dose of 15/92 mg,
66.7% to 70.0% of patients attained ≥5% weight loss
and 47.2% to 48.0% of patients attained ≥10%
weight loss from baseline. Phentermine/topiramate
ER was also associated with dose-dependent
progress in systolic and diastolic blood pressure,
LDL-C cholesterol, HDL-C cholesterol, and
triglycerides compared with the placebo.
Contraindications to phentermine-topiramate include
pregnancy, glaucoma, and hyperthyroidism.
Phentermine/topiramate ER is an FDA schedule IV
controlled substance.[23]
Lorcaserin is a serotonin 2C receptor agonist, which
has an effect on anorexigenic neurons in the
hypothalamus, inhibiting appetite stimulation and
promoting satiety.
Two trials (BLOOM,
BLOSSOM) included obese or overweight
individuals without diabetes. The average body mass
reduction from baseline was 5.8% with the approved
10-mg, twice- daily dose of lorcaserin, compared
with a 2.2% average weight reduction in the placebo
groups. On average, 44.1% of patients attained 5%
weight loss, and 20.5% of patients attained ≥10%
weight loss from baseline in the twice-daily
lorcaserin group, compared with 20.5% and 7.3% of
placebo patients achieving ≥5% and ≥10% weight
loss, respectively. Lorcaserin is a serotonergic drug
and so will cause serotonin syndrome when
combined with medications that act on
neurotransmitter, such as selective serotonin
reuptake inhibitors (SSRIs), selective serotoninnorepinephrine reuptake inhibitors, or drugs that
may affect the clearance of serotonin, such as
lithium, tramadol, or dopamine antagonists.
Lorcaserin also led to significant reductions in BMI,
waist circumference and blood pressure.[23]
The combination of Naltrexone with Bupropion was
approved in 2014. Bupropion is a dopamine and
norepinephrine reuptake inhibitor, which is
commonly used as an antidepressant and for
cessation of smoking. Naltrexone is an opioid
receptor antagonist permitted to treat alcohol and
opioid dependence. Naltrexone and Bupropion
produce a synergistic effect and act in the
hypothalamic melanocortin system and the
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goal setting, social support, slower eating, behavioral
contracting, increase physical activity and education.
Self-monitoring includes keeping daily records of
food intake and exercise that helps recognize the
personal behavior. Stimulus control modifies the
physical environment by purchasing high fiber diet,
avoiding fast foods, not keeping unhealthy and high
calorie foods in the house, and avoiding sweetened
drinks.[18-21]
A weight loss study includes an initial phase (3-6
months) group meeting, which is followed by a
maintenance phase (6-12 months) where participants
who received behavioral intervention revealed a
weight loss of 10.6% in the initial phase and 8.6% in
the follow up phase.[18]
Perri and colleagues concluded that individuals who
attended every other week group maintenance
sessions for the year after the weight reduction,
maintained 13.0 kg of their 13.2 kg end of treatment,
but those who did not receive therapy maintained
only 5.7 kg of 10.8 kg loss.[19]
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Bariatric Surgery
Bariatric surgery should be factored in for all
patients with a BMI of 40 or higher and in patients
with a BMI of 35 or higher with obesity-related
comorbid conditions. Since the bariatric surgery
requirement of a BMI of 35 or higher was
established, emerging evidence has supported the
clinical and cost effectiveness of surgical
intervention in patients with a BMI of 30 to 35 who
do not achieve substantial weight and comorbidity
improvement with nonsurgical methods. However,
most guidelines (and third-party payers) still support
withholding surgical intervention until the BMI is 35
or higher. A multifaceted team with medical,
surgical, nutritional, and psychiatric ability should
evaluate candidates.[24,25]
Bariatric surgical procedures result in reduced
stomach capacity (restriction), malabsorption of
ingested nutrients, hormone changes that suppress
appetite, or a combination of these mechanisms.

Perioperative mortality risk associated with bariatric
surgery is low (<0.3%). Weight loss equal to or
greater than 50% of excess body weight (current
weight minus ideal body weight) is considered a
success. Commonly performed bariatric procedures
include laparoscopic adjustable gastric banding,
Roux-en-Y gastric bypass, biliopancreatic diversion
duodenal switch, and sleeve gastrectomy.[24,25]
Laparoscopic gastric banding, a restrictive procedure
that forms a minute gastric pouch that consists of an
adjustable outlet, which is a silicone belt that is lined
with an inflatable balloon which is fastened into a
closed ring that surrounds the upper stomach. The
band is adjusted (via a port) to achieve early satiety
without dysphagia. Three to 6 years after gastric
banding, excess weight loss is 45% to 72%.[24,25]
Roux-en-Y gastric bypass, a combination restrictive
and malabsorptive procedure, involves creating a
small (30 mL) proximal gastric pouch, which is
separated from the distal side of the stomach and
joined to the Roux limb of small bowel. Digestion
and absorption of nutrients occur in the mid-small
intestine. With Roux-en-Y gastric bypass, stomach
capacity is reduced, as is absorption of calories.
Additionally, delivery of nutrients to the mid-small
intestine triggers hormone changes that suppress
appetite. Three to 6 years after Roux-en-Y gastric
bypass, excess weight loss is 62%.[24,25]
Vertical sleeve gastrectomy is a restrictive procedure
that requires incision of the greater curvature of the
stomach. This procedure involves 70% vertical
gastric resection, which forms an extended, narrow
tubular gastric reservoir that does not have an
intestinal bypass component. This procedure reduces
stomach capacity and suppresses appetite by
removing tissue that produces ghrelin, a hungerstimulating hormone. Excess weight loss 3 to 6 years
after sleeve gastrectomy is 53% to 77%.[24]
One of the most inclusive systematic reviews
examined 136 studies and 22,094 patients which
underwent bariatric surgery. The review concluded
with a high trend towards dissimilar weight loss
outcomes across procedures. Weighted mean
percentage of excess weight loss (%EWL) was 50%
(32% to 70%) for adjustable gastric banding, 68%
(33% to 77%) for Roux¬en-Y gastric bypass, 69%
(48% to 93%) for vertical banded gastroplasty, and
72% (62% to 75%) for biliopancreatic diversion
duodenal switch. Type 2 diabetes rate remission was
different across procedures. The rate was 48% (29%
to 67%) for adjustable gastric banding, 84% (77% to
90%) for Roux¬en¬Y gastric bypass, 72% (55% to
88%) for vertical banded gastroplasty, and 99%
(97% to 100%) for biliopancreatic diversion with
duodenal switch. An identical pattern of disease
remission
was
noticed
for
hypertension,
dyslipidemia, and obstructive sleep apnea, with the
greatest rates of remission seen in patients who had
went through the biliopancreatic diversion with
duodenal switch, followed by Roux¬en¬ Y gastric
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mesolimbic reward system, both regulates food
intake and body weight. On average, based on ITTLOCF data, 52.4% of patients attained ≥5% weight
loss and 28.3% of patients attained ≥10% weight
loss from baseline in the high-dose NaltrexoneBupropion group, compared with 23.6% and 9.7% of
patients in the placebo group, respectively.
Combination
naltrexone-bupropion
is
contraindicated in patients who have epilepsy,
uncontrolled hypertension, and opioid taking
medications.[23]
Liraglutide is an injectable long acting glucagon-like
peptide-1 receptor agonist used to treat type 2
diabetes. It was found that Liraglutide causes weight
loss that prompted the drug company to evaluate the
drug for the treatment of obesity. Liraglutide act in
the hypothalamus and other brain regions that
regulate appetite as well as direct effects on the gut
to reduce food intake via vagal signaling and
delayed gastric emptying, causing early satiety. The
SCALE clinical trials were used to document
liraglutide’s safety and efficiency in the treatment of
obesity and help the drug gain FDA approval for this
indication in 2014 at a 3-mg dose, compared to the
1.8- mg dose used in the treatment of diabetes. In
these trials, treated patients lost an average of 6.5%
of their base line body mass after 1 year of
treatment, compared with a 1.6% reduction in the
placebo group. Approximately 56% of the active
treatment patients were able to achieve ≥5% weight
reduction, with 28% achieving ≥10% weight
reduction from baseline at 56 weeks, compared with
23.4% and 7.9%, respectively, in the placebo groups.
Liraglutide is available only by subcutaneous
injection, requiring patients to learn and implement
injection technique.[23]
Since there is no for sure first-line agent, the
decision for treatment should be based on individual
factors.
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CONCLUSION
Obesity is a widespread disease associated with
multiple comorbid conditions, and so the WHO
(World Health Organization) has declared obesity a
global epidemic and NIH (National Institute of
Health) has clinical guidelines and recommendations
for management of obesity and overweight. A
reduction of 10% body weight will have a significant
beneficial impact on one’s health care cost. It should
be treated forcefully in the same way that it applied
to other diseases. The advances in treatment, such as
life style modification, pharmacology therapy, and
bariatric surgery will prevent the global problem of
overweight and obesity. The increase in awareness
and research will bring about better treatment for the
obese in the next few years.
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bypass, vertical banded gastroplasty, and lastly
adjustable gastric banding.[24]
High quality data from Randomized Controlled
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remission of type 2 diabetes, advancement in long
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incident cardiovascular disease and diabetes,
betterment in sleep apnea and osteoarthritis, and long
lasting
improvements
in
obesity
related
comorbidities between patients who have went
through bariatric surgery compared to non¬surgical
controls.[24,26-28]
In the future, bariatric procedures will base on key
physiological variables that include changes in
ghrelin,
leptin,
glucagon
like
peptide¬1,
cholecystokinin, peptide YY, gut microbiota, and
bile acids.[24]
Patients who undergo bariatric surgery should
continue dietary, physical activity, and behavioral
measures and should receive nutrient replacement
therapy.[25]
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